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Abstract
Epigenetic modulation of gene activity occurs in response to non-genetic factors such as body weight status,
physical activity, dietary factors, and environmental toxins. In addition, each of these factors is thought to affect and
be affected by the gut microbiome. A primary mechanism that links these various factors together in mediating
control of gene expression is the production of metabolites that serve as critical cofactors and allosteric regulators
of epigenetic processes. Here, we review the involvement of the gut microbiota and its interactions with dietary
factors, many of which have known cellular bioactivity, focusing on particular epigenetic processes affected and the
influence they have on human health and disease, particularly cancer and response to treatment. Advances in DNA
sequencing have expanded the capacity for studying the microbiome. Combining this with rapidly improving
techniques to measure the metabolome provides opportunities to understand complex relationships that may
underlie the development and progression of cancer as well as treatment-related sequelae. Given broad reaching
and fundamental biology, both at the cellular and organismal levels, we propose that interactive research programs,
which utilize a wide range of mutually informative experimental model systems—each one optimally suited for
answering particular questions—provide the best path forward for breaking ground on new knowledge and
ultimately understanding the epigenetic significance of the gut microbiome and its response to dietary factors in
cancer prevention and therapy.
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Background
There is intense ongoing research activity to elucidate
the relationship between the human microbiome and
various diseases including cancer. “Microbiome” is a
collective term used for the genes from colonizing
organisms including fungi, viruses, and bacteria, the
latter of which are by far the most populous. The
microbiome are ubiquitous and distinct populations
reside in the oral cavity, stomach, upper and lower
intestine, urinary tract, genitalia, etc. It is increasingly
believed to play a dynamic role in the health of
individuals. The gut is inhabited by the largest variety
of bacteria, which contribute to the metabolism of
different classes of food materials. An overwhelming
100 trillion commensal bacteria live within the human
gastrointestinal tract, constantly exposing the surface
of the intestinal mucosa to the stimulatory effects of
this resident microbiota [86]. Humans are thought to
have evolved a symbiotic relationship with the micro-
biota of the gut; however, the molecular mechanisms
remain poorly understood. DNA-based analysis has
significantly facilitated the identification of bacteria
comprising the microbiome, but understanding func-
tion remains more challenging. For example, indigen-
ous microbiota produce low molecular weight (LMW)
substances that potentially interact with the tissue
cellular environment to modulate signaling pathways
and regulate gene expression. Recently, these LMW
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substances have been shown to influence epigenetic
modifications, chromatin remodeling, and other sig-
naling molecules, ultimately regulating apoptosis, cel-
lular differentiation, and inflammation. Therefore, the
epigenetic changes brought about by microbiota may
contribute to prevention or therapeutic intervention
of cancer or other diseases.
Epigenetics
The molecular mechanism of epigenetics involves many
processes such as DNA methylation, posttranslational
modification of histone proteins, silencing of the extra
copy of the X-chromosome in females, and genomic
imprinting. Non-coding RNAs including microRNA,
small interfering RNA, and long non-coding RNA are
also players that fall under the broader definition of
epigenetics [51].
DNA methylation
DNA methylation is the addition of a methyl group to the
carbon-5 position of the cytosine pyrimidine ring and
occurs predominantly in cytosine guanine dinucleotide-
rich regions known as CpG islands that are found in the
5′ regulatory regions of most genes. The enzymes in-
volved in DNA methylation are called DNA methyltrans-
ferases (DNMTs). TET (10-11 translocation) proteins are
dioxygenase enzymes that hydroxylate 5-methylcytosine
residues to form 5-hydroxymethylcytosine (5hmC). They
use a metabolite intermediate, α-ketoglutarate (α-KG),
and molecular oxygen as enzyme cofactors for this reac-
tion [65]. Bacteria can cause changes in DNA methylation
patterns of host cells by providing epigenetically active
metabolites such as folate, butyrate, and acetate. These
metabolites are essential for DNA methylation. For
example, folate (produced by Bifidobacterium spp.) is a
methyl donor and is necessary for generation of S-ade-
nosylmethionine (SAM) which in turn is a methyl-
donating substrate for DNA methyltransferases [28].
The presence of 5hmC at bivalent loci and DNaseI
hypersensitive sites (HS) might imply that simultaneous
removal as well as renewed deposition of 5mC by
DNMTs is taking place [55]. Thus, DNA methylation is
a dynamic event and several cancers have been associ-
ated with this positional alteration of DNA methylation
[29]. During carcinogenesis, epigenetic switching and
5-methylcytosine reprogramming result in the aberrant
hypermethylation of CpG islands, leading to the unre-
sponsiveness of tumor suppressor genes [85]. In cancers
with a stem cell origin, isocitrate dehydrogenase (IDH)
mutations result in the production of oncometabolite
2-hydroxyglutarate (2HG), leading to global hypermethy-
lation, whereas in tumors with non-stem cell origin an
intact metabolic function of IDH would be necessary to
maintain DNA methylation plasticity [58] (Fig. 1).
Chromatin remodeling and histone modification
Histone acetylation is catalyzed by lysine acetyltransfer-
ases (KATs), which transfer an acetyl group from acetyl
coenzyme A (acetyl-CoA) to lysine residues (Nɛ), with
the concomitant production of CoA [73]. Acetylation is
primarily associated with transcriptional activation, and
most of the acetylation sites occur within the N-terminal
tail of the histones. Acetylation of the histones leads to
increased accessibility of nucleosomal DNA to transcrip-
tion factors. Histone deacetylases (HDACs) are opposite
in function to histone acetyltransferases (HATs) as they
remove the acetyl (acyl) moiety from lysine residues.
Histone acetylation is regulated via the tricarboxylic acid
(TCA) cycle. The gut microbiome produces short-chain
fatty acids that are used to generate ATP via the TCA
cycle. HDACs can also be inhibited by metabolites
produced by the gut microbiome such as butyrate and
propionate. ATP citrate lyase (ACL) uses mitochondrial-
derived citrate to generate acetyl-CoA in the cytoplasm
and nucleus. In the nucleus, HATs transfer the acetyl
group from acetyl-CoA onto histone lysine [77]. Histone
methylation is also an important epigenetic process in
that methylation of histones is effective in recruiting
certain transcription factors to the chromatin. Lysine
and arginine residues can be methylated histone methyl-
transferases. There are additional histone tail modifica-
tions such as histone phosphorylation, ubiquitination,
sumoylation, histone poly-ADP ribosylation, histone
biotinylation, citrullination, and proline isomerization.
Moreover, there is cross-talk not only among the various
histone modifications but also between DNA methyla-
tion and histone modification that often collectively
work in tandem to control gene activity [40]. As for
DNA, methylated histones undergo demethylation by
the JmjC family of dioxygenases that once again depend
on molecular oxygen and α-KG.
Non-coding RNA
RNA that does not code for a protein is termed non-
coding RNA (ncRNA). It is important to note that,
unlike eukaryotes, ncRNAs form a small part of the
prokaryotic genome although small ncRNA has been
reported in bacteria. By contrast, the majority of the
eukaryotic genome is transcribed into ncRNA which
plays a major role in the regulation of messenger RNA
(mRNA) translation. ncRNA can be divided into small
and large ncRNAs. Small ncRNAs, also known as micro-
RNAs (miRNAs), are approximately 18–20 nucleotides
in length and play a critical role in gene regulation [38].
Small interfering RNAs (siRNAs) or PIWI-interacting
RNAs (piRNAs) are key small ncRNAs that play import-
ant roles in several biological processes, especially cancer
[18]. Long ncRNAs are 200 nucleotides in length or
longer. The broad functional repertoire of long ncRNAs
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includes roles in high-order chromosomal dynamics,
telomere biology, and subcellular structural organization
[59]. Exosomes are nanovesicles (30–90 nm in diameter)
secreted by intestinal epithelial cells (IECs) either from
their apical or basolateral side [83]. Through the exo-
somes, proteins, lipids, mRNAs, and miRNAs are released.
Exosomes carry molecules involved in adhesion and
antigen presentation, comprising major histocompati-
bility complex (MHC) class I and class II molecules,
tetraspan proteins, CD26/dipeptidyl-peptidase IV, and
A33 antigen, a molecule essentially restricted to the
intestinal epithelium [31, 52]. Apical secretion of exo-
somes into the lumen have an effect on the function of
distant cells, whereas basolaterally released exosomes
regulate local innate responses [24].
Epigenetic influence through metabolite production by
the gut microbiome
The microbiota of the gastrointestinal tract harbors a
huge collection of beneficial symbionts that aid in diges-
tion, as well as provide a source of various nutrients. In
most mammals, the gut is dominated by four bacterial
phyla that perform these tasks: Firmicutes, Bacteroidetes,
Actinobacteria, and Proteobacteria [45]. These microor-
ganisms produce a number of LMW bioactive sub-
stances such as folate, butyrate, biotin, and acetate that
may participate in epigenetic processes [36].
Folate is a vitamin that accepts one-carbon units from
donor molecules and is involved in many metabolic path-
ways, such as methyl group biogenesis and synthesis of
nucleotides, vitamins, and some amino acids [69]. The
efficiency of DNA replication, repair, and methylation are
affected by folate availability; rapidly proliferating cells
such as leukocytes, erythrocytes, and enterocytes require
large amounts of folate. Folate is widely distributed in the
biological world, intestinal bacteria being one source of
this vitamin [30].
Butyrate is a short-chain fatty acid (SCFA) and a
potent inhibitor of HDACs [12]. The most important
butyrate producer is Faecalibacterium prausnitzii which
belongs to the cluster of Firmicute bacteria, comprised
of Clostridium leptum, Eubacterium rectale, and Clos-
tridium coccoides [49]. Butyrate has the ability to
activate epigenetically silenced genes in cancer cells such
as p21 and BAK [6]. Butyrate has been shown to repress
angiogenesis in vitro and in vivo and reduces the expres-
sion of pro-angiogenic factors such as EGF and HIF 1α
[99]. Increasing the concentration of butyrate in the
colon can play a protective role and prevent cancer, and
its production is dependent on diet and intestinal micro-
flora composition. Butyrate is able to modulate intestinal
microflora through regulation of pH and exerts many
beneficial effects on the intestinal lumen through epi-
genetic mechanisms [94]. The HDAC inhibitor sodium
butyrate is known to increase cell death in human
medulloblastoma cells [62]. We have shown that
epigallocatechin (EGCG) obtained from green tea and
sodium butyrate given at physiological doses achievable
in the human diet induced apoptosis and cell cycle
arrest. They were found to be regulated by decreases in
the epigenetic-modifying enzymes HDAC1 and DNMT1
as well as survivin in colon cancer cells [75].
Biotin is a vitamin that mammalian cells cannot pro-
duce, and they depend on a constant supply of biotin
from the intestinal microbiota to maintain normal levels
of protein biotinylation. Biotinylation is an important
epigenetic process that involves the attachment of biotin
to histone proteins resulting in gene repression, and it also
plays a role in DNA repair and chromatin structure [79].
At the chromatin level, it has been widely demon-
strated that the balance between acetylation and deace-
tylation of histone and non-histone proteins plays a
pivotal role in the regulation of gene expression [67].
HATs and HDACs transfer an acetyl group from acetyl-
CoA to the Ɛ-amino group of lysine and remove the
acetyl group, respectively. CoA is a by-product in this
reaction. The main donor of acetyl groups for formation
of acetyl-CoA in acetylation reactions is the gut micro-
biota [78]. Similar to yeast, acetylation is regulated by
metabolic intermediates of glucose, and one major
enzyme involved is ATP citrate lyase, which converts
citrate produced by the mitochondria into acetyl-CoA
[19]. The ratio of acetyl-CoA to CoA is important for
the regulation of acetylation in response to metabolic
changes [1]. Under conditions of glucose deprivation,
the ratio of acetyl-CoA to CoA drops, and this in turn
affects histone acetylation levels. Studies in yeast have
elucidated that high acetyl-CoA stimulates promoter
histone acetylation [5]. This may have important
implications in cancer studies as oncogenes may make
use of acetyl-CoA metabolism to alter chromatin for
growth [8].
The gut microbiota also contribute to the absorption
and excretion of minerals such as zinc, iodine, selenium,
cobalt, and others that are cofactors of enzymes participat-
ing in epigenetic processes. Moreover, various enzymes
such as the methyltransferases, acetyltransferases, deacety-
lases, Bir A ligase, phosphotransferases, kinases, and syn-
thetases are derived from the gut microbiota. A number
of key energy metabolites including S-adenosylmethionine
(SAM), acetyl-CoA, NAD+, α-KG, and ATP serve as
essential cofactors for many, perhaps most, epigenetic
enzymes that regulate DNA methylation, posttransla-
tional histone modifications, and nucleosome position.
Significant contributors in the epigenomic machinery
are formed during energy metabolism in eukaryotic
cell mitochondria and in the prokaryotic cell mem-
brane signifying that any disorder in these processes
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can lead to a wide variety of diseases associated with
epigenetic modifications [80] (Fig. 2).
Food, the gut microbiota, and epigenetics
It has been shown that maternal and neonatal nutrition
have a major impact on the epigenome of the offspring
in that the food consumed modulates the composition
of the gut microbiota and also the metabolites that they
produce [89]. The gastrointestinal tract of the fetus is
virtually sterile; colonization begins at birth from the
maternal microbiota of the genital tract, colon, and the
overall environment [20]. The bacteria identified include
members of the genera Bifidobacterium, Ruminococcus,
Enterococcus, Clostridium, and Enterobacter. The com-
position of the gut microbiota is profoundly influenced
by the diet of the infant [66]. In breast-fed infants, the
microbiota predominantly consists of Bifidobacteria, and
a plethora of diverse microbiota develops after the intro-
duction of solid food commences. In contrast, the intes-
tines of formula-fed infants are colonized by members of
a variety of bacterial genera, including those of the entero-
bacterial genera Streptococcus, Bacteroides, and Clostrid-
ium, as well as members of the genus Bifidobacterium [20].
By the age of 2 years, the bacterial population of the gut is
established and remains relatively constant throughout life,
though disease processes, surgical interventions, medical
therapies, and epigenetic-modulating factors such as the
diet can influence the gut microbiome. Recent studies have
revealed an association between bacterial predominance
and epigenetic profile. A study on pregnant women with
Firmicutes and Bacteroidetes as the dominant groups in
their gut revealed a correlation between differential methy-
lation status of gene promoters associated with obesity and
cardiovascular disease [42].
The genetic content of an individual’s gut microbial
community is dynamic. It has also been observed that
the incidence of colon cancer is lower in Asian coun-
tries where the diet consists of fruits and vegetables
[20]. Microbiota within the colon convert dietary fiber
into SCFAs by the process of fermentation, and as
discussed previously, one of the predominant SCFAs is
butyrate. Butyrate is naturally produced in the colon
through microbial fermentation. It can induce cell
differentiation [2], apoptosis [25], and histone hypera-
cetylation [7]; thus, it has potential to be a major
chemotherapeutic agent.
High dietary consumption of fat and red meat (espe-
cially processed meat) is associated with increased risk
of colorectal cancer. This effect is thought to be modu-
lated by N-nitroso compounds and heterocyclic aromatic
Fig. 1 The basic process of DNA methylation. S-adenosylmethionine (SAM) is used as the methyl (CH3) donor by the enzyme DNA methyltransferase
(DNMT) to transfer a methyl group to cytosine rings of the DNA strands. TET proteins are dioxygenase enzymes that hydroxylate 5-methylcytosine
residues to form 5-hydroxymethylcytosine (5hmC). They use a metabolite intermediate, α-ketoglutarate (α-KG), and molecular oxygen as enzyme
cofactors for this reaction
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amines [33]. Consumption of red meat delivers L-
carnitine to gut bacteria. These bacteria digest L-carnitine
and convert it into trimethylamine-N-oxide (TMAO). In
studies in mice, TMAO has been shown to cause athero-
sclerosis [39]. Cruciferous vegetables such as cabbage,
broccoli, kale, and cauliflower are rich sources of fiber, lu-
tein, flavonoids, phytosterols, folic acid, sulfur-containing
glucosinolates, and vitamin C, each of which has been as-
sociated with reduced risk of various kinds of cancer [27].
Moreover, sulfur-containing glucosinolates can be con-
verted to biologically active compounds such as indoles,
nitriles, and isothiocyanates (ITCs) by β-thioglucosidases
produced by the gut microbiome [61]. The glucosinolate
of sulforaphane (SFN) is contained in several cruciferous
vegetables but is present in highest concentration in
broccoli [97]. ITCs can also exert epigenetic effects
via modulation of DNA methylation. For example, DNA
methyltransferases are downregulated by SFN, which can
lead to site-specific CpG island demethylation in the
telomerase reverse transcriptase (TERT) gene and a reduc-
tion of its cancer-sustaining expression [57].
Cancer and the gut microbiome
Gastric cancer
Gastric cancers are often caused by infection with
Helicobacter pylori which induces chronic gastritis and
peptic ulcers [100]. Virulent strains harbor cytotoxin-
associated gene pathogenicity island (CagPAI) that
encode components of type IV secretion system (T4SS)
[13]. Cag A oncoproteins are transported across the host
cell membrane via the type IV secretion system T4SS.
Studies have shown that H. pylori CagPAI dependently
induces dephosphorylation of histone H3S10, H3 threo-
nine 3, and deacetylation of H3K23 in gastric epithelial
cells but does not affect nine other distinct histone
modifications [14]. Microbial pathogens often manipu-
late host cell mechanisms through histone modifications.
Hence, targeting these epigenetic modifications may be
one of the important therapeutic strategies to stop the
infection. Dietary phytochemicals with HDAC- or HAT-
inhibiting properties may play a pivotal role in altering
these histone modifications.
Colon cancer
Intestinal environmental changes are keys to progres-
sion toward adenoma and subsequently to colon can-
cer. A recent study has shown significant changes in
fecal microbiota, especially decreases in fecal SCFA
concentrations (acetate, propionate, and butyrate) and
significant increases in fecal pH in colon cancer
patients compared with healthy individuals [63]. It was
also observed that the count of obligate anaerobes was
Fig. 2 The molecular interaction of the gut microbiota is greatly influenced by the dietary compounds consumed. The microbes residing in the
human gut produce a number of low molecular weight molecules such as butyrate, folate, propionate, and biotin. These compounds either
directly bring about epigenetic modifications such as changes in DNA methylation and histone acetylation or indirectly act via activation or
inhibition of certain enzymes such as DNMTs, HDACs, or even hTERTs. Me DNA methylation, Ac histone acetylation
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significantly decreased in the case of colon cancer [56].
It has been hypothesized that it may be possible to
prevent colorectal cancer by improving the intestinal
environment, as the decrease in count of microbiota
may be one of the causes of colon cancer development
and progression. Adding probiotics to the diet is specu-
lated as a way to reduce the risk of colon cancer [96].
In addition, adding cruciferous vegetables and green tea
polyphenols may further bring about epigenetic modifi-
cations in the bacterial DNA or the genes that they
target [34]. The microbiome may undergo significant
changes in other forms of cancer such as breast cancer.
It has often been observed that patients on chemother-
apy have diarrhea and irritable bowel syndrome. Studies
have shown considerable changes in the microbiome of
the patients undergoing chemotherapy [84]. Therefore,
improving the quality of the intestinal microbiota may
be a therapeutic option to alleviate some of these side
effects of chemotherapy and improve the quality of life
of these patients. The alteration of the gut microbiome
has been shown in several diseases including cancer as
is summarized in Table 1.
A study of the stool microbiome and metabolome
differences between colorectal cancer (CRC) and healthy
adults showed that several butyrate-producing bacteria
were underrepresented in CRC samples, whereas mucin-
degrading species Akkermansia muciniphila were about
fourfold higher [95]. There is evidence to suggest that
induction of pro-inflammatory responses by commensal
bacteria contributes to tumor initiation and development
[16]. Production of genotoxins and DNA-damaging
superoxide radicals by Enterococcus faecalis are also
mechanisms by which commensals can contribute to
CRC development [23]. Irritable bowel syndrome includ-
ing ulcerative colitis and Crohn’s disease also predis-
poses to CRC [72]. A study showed that infection with
Helicobacter hepaticus in Rag 2−/− mice led to increased
inflammation and elevated TNF-α production [17].
SCFAs such as butyrate, acetate, and propionate, which
are fermentation products from dietary fibers by colonic
gut microbiota, can regulate neutrophil function and
migration and exhibit anti-inflammatory activity [15].
Butyrate can induce TNF-α to potentiate cell death [35]
and can, via miRNA-dependent p21 gene expression
activity, lead to colon cancer prevention [32].
Hormone-dependent, breast, ovarian, and endometrial
cancer
There is an increasing interest in other cancers that may
have directly or indirectly been influenced by the gut
microbiome. The gut microbiome modulates estrogen
metabolism and contributes to the proportion of re-
circulated and excreted estrogen and estrogen metab-
olites [22]. The introduction of bacteria in germfree
mice led to a significant rise in the reproductive capacity
of the germfree mice [81]. The capacity of reproduction
of germfree mice is generally lower. However, addition
of bacteria showed normalization in the estrous cycle
and a significant rise in copulation and implantation
rates. Also, there were studies that showed that a
reduction in the population of specific gut bacteria in
humans causes increased fecal excretion of conjugated
estrogens and decreases in urinary estrogens. Human fecal
extracts metabolize plasma estrone (E1), 17β-estradiol
Table 1 Alteration of gut microbiome in human diseases
Disease Microbiome alteration Reference
Irritable bowel syndrome Increased ratio of the Firmicutes to Bacteroidetes (Rajilić-Stojanović, Biagi et al. 2011) [70]
Crohn’s disease Increased Clostridium species, Ruminococcus torques,
and E. coli
(Martinez‐Medina, Aldeguer et al. 2006) [53]
Gastric cancer H. pylori induces production of pro-inflammatory
cytokines
(Tsuji, Kawai et al. 2003) [88]
Colorectal cancer Abundance of Fusobacteria and Coriobacteria (Castellarin, Warren et al. 2012) [9]
Obesity Reduced ratio of Bacteroidetes to Firmicutes (Ley, Bäckhed et al. 2005) [44]
Type 1 diabetes Altered gut permeability to mannitol and lactulose (Kuitunen, Saukkonen et al. 2002) [41]
Atherosclerosis Metabolism of phospholipids by gut microbiota to
trimethylamine-N-oxide
(Loscalzo 2011) [48]
Rheumatoid arthritis Less Bifidobacteria and bacteria of the Bacteroides-
Porphyromonas-Prevotella
(Vaahtovuo, Munukka et al. 2008) [90]
Autism Higher number of Clostridium species known to
produce tetanus neurotoxin (TeNT)
(Parracho, Bingham et al. 2005) [64]
(Bolte 1998) [4]
Chronic fatigue syndrome Lower levels of Bifidobacteria and small-intestinal
bacterial overgrowth
(Logan, Venket Rao et al. 2003) [47]
Alzheimer’s disease Excess ammonia production by gut microbiota (Samsel and Seneff 2013) [76]
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(E2), and 16α-hydroxyestrone in vitro and lead to the
inter-conversion of E1 and E2 and the reduction of 16α-
hydroxyestrone to estriol (E3), 16-oxoestradiol to 16-
epiestriol, and 15α-hydroxyestrone 15α-hydroxyestradiol.
The human gut microbiome can influence the estrabo-
lome. This is due to the presence of aggregate of en-
teric bacterial genes whose products are capable of
metabolizing estrogen. Some bacterial species possess
β-glucuronidases and β-glucuronides which are the
enzymes involved in estrogen deconjugation and
conjugation [68]. Deconjugation reactions may result
in greater reabsorption of free estrogens, leading to
the development of estrogen-driven cancers such as
breast, ovarian, and endometrial cancers. Phase II
hepatic conjugation reactions of E1 and E2 include
methylation via catechol-O-methyltransferase (COMT)
and glucuronidation via uridine 5′-diphospho-glucurono-
syltransferase. COMT converts genotoxic catechol estro-
gens to their inactive methoxy derivatives, 2-MeOE2 and
4-MeOE2. Thus, consumption of certain plant-based diet
(such as tomato) containing high levels of O-methyltrans-
ferases may reduce exposure to potentially mutagenic
estrogen metabolites [50]. Daidzein is converted by gut
microflora into dihydrodaidzein, S-(−)equol (70 %)
and O-desmethylangolensin (5–20 %) [37]. Studies on
soy isoflavones have shown that the ability to produce
equol varies (only 30–50 % of US populations are
equol producers) and is primarily dependent on intes-
tinal bacterial composition of an individual [3, 43]. It
has been shown that the amount of urinary equol
excretion is correlated with a reduced risk of breast
cancer, and epigenetic modifications may play a role in
impacting cancer secondary to changes in metabolites
[74]. The study of these interactions may provide new
avenues for therapeutic research. Colonization with
specific bacteria that can modulate levels of certain
metabolites may be another way to target diseases
such as cancer.
Liver cancer
Toll-like receptors (TLR4) are activated by lipopolysac-
charide (LPS) from gut bacteria and may contribute to
injury and inflammation-driven tumor promotion in the
liver [11]. Epigenetic regulation of TLR4 gene expression
in intestinal epithelial cells can act as one mechanism
for maintaining intestinal homeostasis by suppressing
excessive responses to the commensals and regulating
mucosal inflammation in the gut [87]. Dietary regulation
of epigenetic modification may be useful for the preven-
tion of liver cancer. SCFAs produced by gut microbiota
bind G protein-coupled receptor 43 (GPCR43), and this
interaction affects inflammatory responses [46]. GPR43-
deficient (Gpr43−/−) mice showed exacerbated inflamma-
tion in models of colitis, arthritis, and asthma [92].
These effects appear to relate to increased production of
inflammatory mediators by Gpr43−/− immune cells and
increased immune cell recruitment [93].
Lung cancer
Chronic inflammation plays a central role in the patho-
genesis of chronic obstructive pulmonary disease (COPD)
and lung tumorigenesis. Chromatin modifications and
other epigenetic changes, angiogenesis, and apoptosis are
crucial in the development of COPD and lung cancer [98].
Recent studies have established a role of miRNA as a
pathogenic link between COPD and lung cancer [82].
Hence, emerging science should explore the relationship
between the gut microbiome, its various metabolites, and
cancer epigenetics (Table 2).
Conclusion
The indigenous microbiota plays a very important role
in either directly or indirectly affecting epigenetic
processes in the body. The LMW molecules produced
by the microbiota of the gut participate in various
molecular pathways and thus are implicated in the
etiology of many diseases. Diet also plays a vital role in
maintaining the health of an individual as the dietary
components directly interact with the LMW molecules
produced by the microbiota. Thus, studying the inter-
relationship between the human gut microbiota, their
genetic makeup, the epigenome, and dietary components
may offer new therapeutic options for treating diseases.
Studies on family clusters of nonagenarian and centenar-
ian siblings have shown that apart from inheriting excep-
tional gene groups, behavior and lifestyle have contributed
to their aging well phenotype [71]. Thus, the study of this
interrelation is important for disease prevention. The
Human Microbiome Project aims at a better understand-
ing of the roles of microbes on human biology including
their relationship with health and disease [91]. The human
intestinal microbiome will pave the way leading to a new
frontier in human biology, in which the human genome
and the bioactive products from the intestinal microbiome
are tightly linked together as an integral part of the
“human metagenome.” Bioactive products such as LMW
compounds may bring about epigenetic changes that
directly and/or indirectly modify various epigenetic path-
ways through hormonal intermediates or immunological
messengers. The study of epigenetic changes dependent
on the microbiome is especially important for the study of
cancer. A good animal model is essential for the study of
the interactions among diet, gut microbiome, and cancer.
The majority of anaerobic bacteria present in our digestive
tract cannot be cultivated on existing media. Zebrafish
can be a good model for microbiome studies as they share
a great deal of homology with mammals. Most zebrafish
genes have mammalian orthologs, and most epigenetic
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Table 2 Gut microbiota and its emerging science in cancer epigenetics
Cancer Link to gut microbiome Link to epigenetics Possible therapy Reference
Gastric H. pylori causes gastric pathology
by injecting about 128 kDa Cytotoxin-
associated gene A (Cag A) protein
which enhanced c-Myc and
DNMT3B expression
H. pylori increased histone H4
acetylation in the promoter
region of p21 thereby increasing
p21 expression
Dietary compounds that have
HAT-inhibiting activities
(Hayashi, Tsujii et al. 2012) [26]
(Ding, Goldberg et al. 2010) [13]
(Fehri, Rechner et al. 2009) [21]
Colon Elevated TNF-α expression in
the colon
TNF-α-suppressed differentiation
and potentiated cell death induced
by butyrate (NaBt) in both
adenocarcinoma HT-29 and fetal
FHC human colon cells in vitro
Sodium butyrate which is an
HDAC inhibitor can induce
TNF-α to potentiate cell death
(Hýžd’alová, Hofmanova et al.
r2008) [35]





that participate in estrogen
conjugation and deconjugation
Phase II hepatic conjugation








that can inactivate catechol
estrogens
(Plottel and Blaser 2011) [68]
(Mageroy, Tieman et al. 2012) [50]
Liver TLR4 activation by LPS from gut
bacteria contributes to tumor
promotion
Epigenetic regulation of TLR4
gene expression in intestinal
epithelial cells (IECs) can act as
one mechanism for maintaining
intestinal homeostasis by
suppressing excessive responses
to the commensals and
regulating mucosal inflammation
in the gut
(Dapito, Mencin et al. 2012) [11]
(Takahashi, Sugi et al. 2011) [87]
Lung SCFAs produced by gut microbiota
bind GPCR43 which affects
inflammatory responses. GPR43-
deficient (Gpr43−/−) mice showed
exacerbated or unresolving
inflammation in models of colitis,
arthritis, and asthma
SCFAs are known to have HDAC-
inhibiting activities




(Maslowski, Vieira et al. 2009) [54]
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regulators are highly conserved: there are 75 and 92 %
identity between zebrafish and human DNMT1 and
HDAC1, respectively [60]. Some other useful models for
exploring host-microbiota interactions are fruit fly and
yeast. However, most extensively used models for the
study of cancer are rodents. Human fecal samples can be
transplanted into rodents that are raised in a germfree
environment where they have no exposure to microbes.
Such animals, called gnotobiotic mice, are helpful in study-
ing microbial community compositions by varying diet
and disease parameters. These mice can harbor the micro-
bial community in humans and hence are called “human-
ized mice.” It is, however, important to note that although
germfree mice do not harbor live bacteria, they still are
exposed to a minimum amount of microbes in food,
water, and bedding. They can be further induced with can-
cer cell line xenografts, and different dietary interventions
can be introduced for effective study of intestinal
microbial epigenetics [10]. Epigenetic dietary phytochemi-
cals such as SFN from broccoli sprouts, EGCG from green
tea, or genistein from soy products may positively enhance
the interaction among metabolism, diet, gut microbiome,
and epigenome. This can be very useful to treat a variety
of cancers such as colon, lung, or even breast cancers
where the current chemotherapy drugs such as doxorubi-
cin/docetaxel can strip the body of its essential micro-
biome. Administering an “epigenetic diet” along with
conventional treatment can be effective in enhancing the
quality of the microbiome in cancer patients. Thus, by
manipulating both the microbiome and the diet, we may
discover novel therapies that act through epigenetic path-
ways and add to our armamentarium against cancer.
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